

October 12, 2010

Press Release

Taisho Toyama Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation

**Launch New 1000 mg Dosage Formulations of Pasil® and Pazucross®
Injectable New Quinolone Antibacterial Agents on October 13**

Taisho Toyama Pharmaceutical Co., Ltd. (President: Akira Ohira, hereinafter: Taisho Toyama Pharmaceutical), and Mitsubishi Tanabe Pharma Corporation (President & CEO: Michihiro Tsuchiya, hereinafter: Mitsubishi Tanabe Pharma) announced today that two companies will launch new 1000 mg dosage formulations of new quinolone antibacterial agents (generic name: pazufloxacin mesilate), Pasil® Injection 1000 mg and Pazucross® Injection 1000 mg on October 13, 2010, respectively.

In connection with additional indication and the dosage escalation, approved as of July 23, 2010, 1000 mg bag will be added as new dosage formulations to Pasil Injection 300 mg, 500mg and Pazucross Injection 300mg, 500mg that have been marketed since September 2002.

Newly launched 1000 mg dosage formulations were developed by Toyama Chemical Co., Ltd. (President: Masuji Sugata, hereinafter: Toyama Chemical) and Mitsubishi Tanabe Pharma in response to demand from the Japanese Society of Chemotherapy. In recent years medical professionals requested increased dosage of the agent to obtain greater efficacy, while securing safety, in the treatment of severe or intractable infectious diseases. The 1000 mg bag is very convenient formulation that satisfies and contributes the needs on the medical front.

New Pasil® 1000 mg and Pazucross® 1000 mg will be manufactured by Toyama Chemical and Mitsubishi Tanabe Pharma, as with conventional 300 mg and 500 mg products, respectively, and will be marketed by Taisho Toyama Pharmaceutical and Mitsubishi Tanabe Pharma, respectively.

<Media enquiry>

Taisho Toyama Pharmaceutical Co., Ltd.
Tel: +81-3-3985-8100

Mitsubishi Tanabe Pharma Corporation
Tel: +81-6-6205-5211